Want to see DXCM full AI Analyst Report?
Earnings Data
Report Date
Jul 23, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.61Last Year’s EPS
0.48Same Quarter Last Year
Strong Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a largely positive view: strong revenue growth (15% reported, 12% organic), robust margin expansion (gross margin improvement of ~600 bps and large increases in operating income and EBITDA margins), record global new patient starts, solid cash generation (~$2.4B) and successful product and reimbursement catalysts (G7 15-day uptake, Prime Therapeutics coverage, international wins). Key risks and constraints—chiefly CMS timing uncertainty, a potential 50–100 basis point gross margin headwind from fuel/resin costs, reliance on tenders for international growth, and the need to sustain record new patient starts in the U.S.—temper but do not outweigh the positive operational and financial momentum communicated on the call.Company Guidance
Revenue Growth (Q1 2026)
Worldwide revenue of $1.19 billion, up 15% year-over-year (YoY) vs Q1 2025; organic revenue growth of 12% (organic excludes FX and recent M&A/divestitures).
U.S. and International Performance
U.S. revenue of $832 million, up 11% YoY; International revenue of $360 million, up 26% YoY (international organic growth 17%). Growth was broad-based with notable strength in markets like France and Canada.
Material Margin Expansion and Profitability
Gross profit of $757.4 million (63.5% of revenue) versus 57.5% in 2025 (+600 basis points). Operating income of $264.4 million (22.2% of revenue) compared with $143.1 million (13.8% in 2025). Adjusted EBITDA of $364.5 million (36.0% of revenue) vs $230.4 million (22.2% in 2025). Net income of $216.3 million ($0.56 per share), a 75% increase YoY.
Strong Cash Generation
Closed the quarter with approximately $2.4 billion in cash and cash equivalents, up >$400 million versus year-end 2025, driven by significant free cash flow in Q1.
Reaffirmed Revenue Guidance and Raised Margin Targets
Reaffirmed full-year revenue guidance of $5.16–$5.20 billion (growth of 11%–13%). Maintained non-GAAP gross profit margin guidance of 63%–64% and increased non-GAAP operating profit margin guidance to 23%–23.5% and adjusted EBITDA margin guidance to 31%–31.5%.
Successful G7 15-Day Product Launch and Adoption
Broad U.S. rollout of G7 15-day with excellent customer and physician feedback; improved sensor algorithm and longer wear time cited as drivers for new patient starts and conversions. Management estimates ~50% of the installed base will convert to the 15-day product by year-end.
Reimbursement Wins and Access Expansion
Prime Therapeutics announced to begin covering CGM for all people with diabetes in the commercial type 2 non-insulin population this summer, putting DexCom on track for >7 million type 2 non-insulin commercial lives covered by year-end. International reimbursement wins helped drive OUS growth.
Strengthening Clinical Evidence
12-month type 2 non-insulin registry showed a statistically significant A1c reduction; a randomized controlled trial (RCT) in type 2 non-insulin patients will be read out at ADA 2026, expected to bolster payer adoption and reimbursement.
Operational and Product Improvements
Operational efficiencies (manufacturing throughput, normalized freight, inventory improvements) drove margin gains. May manufacturing began with new patch adhesive technology to improve sensor survivability; software updates (Stello redesign with AI-driven insights) and Smart Basal pilot advancing.
DXCM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DXCM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $59.55 | $61.35 | +3.02% |
Feb 12, 2026 | $65.08 | $70.02 | +7.59% |
Oct 30, 2025 | $68.20 | $58.22 | -14.63% |
Jul 30, 2025 | $89.06 | $80.77 | -9.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Dexcom (DXCM) report earnings?
Dexcom (DXCM) is schdueled to report earning on Jul 23, 2026, After Close (Confirmed).
What is Dexcom (DXCM) earnings time?
Dexcom (DXCM) earnings time is at Jul 23, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DXCM EPS forecast?
DXCM EPS forecast for the fiscal quarter 2026 (Q2) is 0.61.
